Consolidated Statements of Changes in Stockholders' Deficit - USD ($)		Common Class A [Member] Common Stock [Member]	Common Class B [Member] Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Mar. 10, 2022
Balance, shares at Mar. 10, 2022
Accretion of Class A common stock subject to redemption to redemption amount				(9,208,780)	(3,911,841)	(13,120,621)
Net income					552,813	552,813
Issuance of Class B common stock to Sponsor	[1]		$ 288	24,712		25,000
Issuance of Class B common stock to Sponsor, shares			2,875,000
Issuance of Placement Units		$ 63		6,343,687		6,343,750
Issuance of Placement Units, shares		634,375
Issuance of Representative shares		$ 6		67,269		$ 67,275
Issuance of Representative Shares, shares		57,500				57,500
Proceeds allocated to Public Warrants				2,978,500		$ 2,978,500
Value of offering costs allocated to the fair value of equity instruments				(205,388)		(205,388)
Balance at Dec. 31, 2022		$ 69	$ 288		(3,359,028)	(3,358,671)
Balance, shares at Dec. 31, 2022		691,875	2,875,000
Shareholder non-redemption agreement				709,691		709,691
Shareholder non-redemption agreement				(709,691)		(709,691)
Conversion of Class B common stock to Class A common stock		$ 288	$ (288)
Conversion of Class B common stock to Class A common stock, shares		2,874,999	(2,874,999)
Excise tax					(1,000,789)	(1,000,789)
Accretion of Class A common stock subject to redemption to redemption amount					(1,975,219)	(1,975,219)
Net income					339,767	339,767
Balance at Dec. 31, 2023		$ 357			$ (5,995,269)	$ (5,994,912)
Balance, shares at Dec. 31, 2023		3,566,874	1

[1] Includes up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 5). The underwriters exercised their over-allotment option in full on August 9, 2022; thus, no shares of common stock remain subject to forfeiture as of August 9, 2022 (see Note 5).